Evidence map›Paper›PMID 29147275›Full record

ArticleWorld journal of oncology2012

Successful Retreatment With ADOC Chemotherapy in Relapsed Thymic Carcinoma: Experiences in Two Cases.

Yayoi Nomura, Tomonobu Koizumi, Akihiro Kitaguchi, Toshimichi Horiuchi, Shintarou Kanda, Hiroshi Yamamoto, Masayuki Hanaoka, Keishi Kubo

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yayoi NomuraFirst Department of Internal Medicine, Shinshu University School of Internal Medicine, 3-1-1, Asahi Matsumoto, Japan.
Tomonobu KoizumiFirst Department of Internal Medicine, Shinshu University School of Internal Medicine, 3-1-1, Asahi Matsumoto, Japan.
Akihiro KitaguchiFirst Department of Internal Medicine, Shinshu University School of Internal Medicine, 3-1-1, Asahi Matsumoto, Japan.
Toshimichi HoriuchiFirst Department of Internal Medicine, Shinshu University School of Internal Medicine, 3-1-1, Asahi Matsumoto, Japan.
Shintarou KandaFirst Department of Internal Medicine, Shinshu University School of Internal Medicine, 3-1-1, Asahi Matsumoto, Japan.
Hiroshi YamamotoFirst Department of Internal Medicine, Shinshu University School of Internal Medicine, 3-1-1, Asahi Matsumoto, Japan.
Masayuki HanaokaFirst Department of Internal Medicine, Shinshu University School of Internal Medicine, 3-1-1, Asahi Matsumoto, Japan.
Keishi KuboFirst Department of Internal Medicine, Shinshu University School of Internal Medicine, 3-1-1, Asahi Matsumoto, Japan.
Shinshu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The optimal second-line chemotherapeutic regimen for thymic carcinoma remains uncertain and predictive factors for the response have not been identified. We encountered two cases of relapsed thymic carcinoma with recurrence 1.5 and 8 years after initial response to cisplatin/doxorubicin/vincristine/cyclophosphamide (ADOC) chemotherapy. Both cases were successfully retreated with ADOC. Our observations suggest that relapsed thymic carcinoma occurring a long treatment-free time from the initial response may be sensitive to the previous chemotherapy. We described two cases of relapsed thymic carcinoma successfully retreated with ADOC chemotherapy. Both patients had partial response to initial ADOC and long disease free times.

Indexed as

ChemotherapySensitive relapseThymic cancer

Identifiers

PMID29147275
PMCPMC5649833
OpenAlexW2171348686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.